Scholar Rock - Positive Top-Line Results from TOPAZ Trial - Type 2 and 3 SMA

Health Professional Radio - Podcast

Dr. Yung Chyung, Chief Medical Officer at Scholar Rock, a clinical-stage biopharmaceutical company discusses the positive 12-month top-line results from the TOPAZ Phase 2 clinical trial evaluating apitegromab (SRK-015) in patients with Type 2 and Type 3 spinal muscular atrophy (SMA).

Dr. Yung H. Chyung has served as Chief Medical Officer since February 2016 and leads the clinical development of pipeline candidates and medical affairs. Prior to joining Scholar Rock, Yung served in roles of increasing responsibility at Dyax Corp. (acquired by Shire Plc in January 2016) from 2011 to February 2016, most recently serving as Vice President of Medical Research, where he was responsible for clinical research and medical affairs. From 2010 to 2011, he worked at Genzyme Corporation where he was responsible for medical affairs efforts globally for multiple rare disease programs. Yung earned his MD from Harvard Medical School and completed his internal medicine residency and allergy and immunology fellowship at Massachusetts General Hospital. He holds an AB in Biochemical Sciences from Harvard College.